

BRAIN Biotech AG

Creating a #BiobasedFuture

Capital Markets Day 2023

Zwingenberg, February 27, 2023

WE SUPPORT



Since 2021 we have been committed to the UN Global Compact corporate responsibility initiative and its principles in the areas of human rights, labor, the environment and anti-corruption.




Efficient & Transparent Organization: Performance Made Visible

Michael Schneiders, CFO

Efficient & Transparent Organization

aligning external reporting with business accountability




*TMS+ = Tech Access Fees, Royalties & Production Strain Licensing

All numbers FY '21/22

Efficient & Transparent Organization

harvesting clearly defined synergies within the group, sustainability embedded



Efficient & Transparent Organization

clear management accountability

Adriaan Moelker Group CEO		BRAIN Biotech AG Creating a #BiobasedFuture		Michael Schneiders Group CFO
------------------------------	--	---	---	---------------------------------

BioProducts
Application Based Fermentation & Formulation

BioScience
Bespoke Customer Solutions

BioIncubator
Building the Future in Biotech



Rod Sears-Black
MD



Dr. Martin Langer
MD



Dr. Alexander Pelzer
Head R&D



Dr. Lutz Müller-Kuhr
CEO



Dr. Martin Langer
MD



Dr. Alexander Pelzer
Head R&D




Dr. Michael Krohn,
Co-CEO



Lukas Linnig,
Co-CEO

Efficient & Transparent Organization

significantly reducing complexity



Today


- 17 entities
- High complexity & costs

FY 2022/23

- 9 entities including new Akribion Genomics
- Significantly improved efficiency & manageability
- Lower running costs

FY 2021/22

- Active portfolio management:
 - Weriol Group / Bretec purchase
 - L.A. Schmitt disposal



Efficient & Transparent Organization

gaining financial flexibility

Status Quo

Holding (AG) is highly loss making due to:


- Holding costs
- Incubator costs
- M&A costs
- Minority buyouts

Group Sources of financing:

- Equity only at AG level
- No debt capacity at AG level due to loss situation
- Limited debt capacity at and dividend upstreaming capacity from subsidiaries due to minorities

Efficient & Transparent Organization

One BioProducts creation is enabling increased financial flexibility at AG level



Efficient & Transparent Organization

gaining financial flexibility via strategic reorganization

BRAIN Biotech AG Holding

- ❖ Active portfolio management
- ❖ Facilitate cross-divisional synergies
- ❖ Drive M&A
- ❖ Equity financing for strategic considerations

One BioProducts



- High organic growth
- Bolt-on M&A
- Solid cash flow
- Good debt capacity
- Dividend upstreaming to holding

BioScience



- Engine for One BioProducts & Incubator
- Enabling BRAIN as integrated solutions provider
- TMS+* driving future profitability

BioIncubator



- Further increased focus
- Risk sharing with partners
- IP driven / capital light



- Spin-out
- Growth financing & focus
- Therapeutics Opportunity



- Evaluate all options post Phase 2a
- De-risk financially
- Keep royalty upside



- TMS / Milestones / Royalty
- Clinical fully partner driven
- Explore similar projects

*TMS+ = Tech Access Fees, Royalties & Production Strain Licensing

Efficient & Transparent Organization

key takeaways strategic reorganization

- ✓ **Transparency:** improved reporting for all stakeholders
- ✓ **Alignment:** internal organization with external reporting
- ✓ **Operational business model:** BRAIN Biotech as integrated solutions provider with technology USPs
- ✓ **Focused:** very attractive multi niche-markets in F&B, Healthcare and Environment
- ✓ **BRAINimpact:** servicing the megatrends of tomorrow, sustainability as an enabler
- ✓ **Synergies:** clearly identified between all business segments
- ✓ **Complexity:** significantly reduced in the group
- ✓ **Financial flexibility:** increased throughout the group and at the AG level
- ✓ **Equity story:** simplified for new investors